nanotechnology and new perspective in cancer therapy Treviso 20-21 - - PowerPoint PPT Presentation

▶
nanotechnology and new perspective in cancer therapy
SMART_READER_LITE
LIVE PREVIEW

nanotechnology and new perspective in cancer therapy Treviso 20-21 - - PowerPoint PPT Presentation

Nov 11, 2023 154 likes •397 views

NANO futures EITP The EU scenario in nanotechnology and new perspective in cancer therapy Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015 What Why How Example Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015 NANO futures environment its an

slide-1
SLIDE 1

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

NANOfutures EITP

The EU scenario in nanotechnology and new perspective in cancer therapy

slide-2
SLIDE 2

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

What Why How Example

slide-3
SLIDE 3

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

Plus close cooperation with 11 European Technology Platforms From research institute and universities NANOfutures environment it’s an HUB for the NANOtechnologies where several actors can interact From industrial association and networks From industrial sectors,

slide-4
SLIDE 4

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

The Platform structure guarantees a cross-cutting approach: 10+1 Horizontal Working Group

Platform Members

Brokerage Event V4N Workshop

INDUSTRIALIZATION Tech.Transfer and Innovation Financing NETWORKING SKILLS AND EDUCATION RESEARCH and TECH. COMMUNICATION SAFETY STANDARDIZATION REGULATION

355 58 495 442 235 645 349 319 268 459

CRITICAL ROW MATERIALS SOCIETAL ENGAGEMENT NEW

slide-5
SLIDE 5

Treviso 20-21 Nov. 2015

NANOfutures is close to you!

26 Local Contact points and more to come!

NANOfutures

NANOfutures

Platform Network

The lighthouse acts as a clear connection helping to translate activities/actions to the countries/ regions and vice versa.

slide-6
SLIDE 6

Treviso 20-21 Nov. 2015

WHY?

slide-7
SLIDE 7

Treviso 20-21 Nov. 2015

NANOfutures Vision

NANOfutures is the European Technology Integrating and Innovation Platform on nanotechnology. Its main objective is to facilitate the nanotechnology development and commercialization by connecting all relevant nanotechnology Deep Knowledge Cost of Research Industrial Profit Safety Regulation Quick access to Market

All the main actors need to be involved in the process of tracing a Roadmap

Companies ¡ and ¡Industrial ¡ Clusters ¡ Research ¡ Institution ¡and ¡ HE ¡ Policy ¡Maker ¡ and ¡ Governments ¡ NANOfutures fosters a responsible development

  • f the Nanotechnologies by balancing:
slide-8
SLIDE 8

Treviso 20-21 Nov. 2015

Evolving VISION

VALUE CHAIN PRODUCT CHAIN SOCIETAL CHAIN

Knowledge Design Growth Market Product Sustainability

NANOfutures defines development of products in a systematic and comprehensive way considering that each major step of a Product Value Chain has its subchain of activities

slide-9
SLIDE 9

Treviso 20-21 Nov. 2015

HOW?

slide-10
SLIDE 10

Treviso 20-21 Nov. 2015

Roadmapping Activity

  • Bottom-Up
  • Open and Inclusive
  • Cross-Sectorial
  • Systematic

Approach

  • Market addressed Value Chains
  • Actions Sequences in Short-Medium-Long Term
  • TRL targets

Structure

2012 2015

slide-11
SLIDE 11

Treviso 20-21 Nov. 2015

Roadmapping Activity

New Actions in the four VC Examples of Pilot Lines Market scenario of those Pilot Lines Consortia examples of those Pilot Lines WHAT’S NEW IN THE IMPLEMENTATION ROADMAP

slide-12
SLIDE 12

Treviso 20-21 Nov. 2015

Roadmapping Activity

MEDICINE AND PHARMA IN THE ROADMAPS

  • Regenerative medicine, diagnostics and drug delivery
  • Nanoporous and nano- enabled textiles structures and

surfaces for smart biomaterials

  • Microfluidic advanced systems for in vitro diagnostics
  • Smart chemical and bio sensors for multi-parameter

measurements (multiplexing)

  • Nano- particles/capsules/nanofluids for to be used as

nanopharmaceuticals and/or contrast agents

ACTIONS ARE DETAILD TOWARD:

Nanostructured Coating Microfluidics, Lab on chips Nano-pharmaceutical and contrast agent for theranostics

slide-13
SLIDE 13

Treviso 20-21 Nov. 2015

Roadmap Focus: VCs & Markets

Cross Sectorial Non-Technological Actions VC6 Integration of nano Direct manufacturing Finished net shaped Semi finished Catalysis and filtration 3d structures for

  • ptoelectronic

VC3 Structured Surfaces Energy (PV

batteries, harvesting)

ICT (Nanoelectronics, photonics) Transportation Construction and buildings Textile and passive funct. Medicine (Bio-sensors,

regen. medicine)

VC4 Alloys Ceramics, Intermetallics

Energy Harvesting & Conversion

VC7 Infrastructure for Multiscale Modelling and Testing

Complex Adaptive Systems for complete product design

VC2 - Nano- enabled surfaces for multi-sectorial applications

Plasma and Vacuum Engineered Surfaces Wet Engineered Surfaces

VC1 - Lightweight multifunctional materials and sustainable composites Textile and sport sector Energy Packaging

Transportation

ICT VC5 Functional Fluids Construction and building Transportation Medicine &Pharma

Household Cleaning Cosmetics

slide-14
SLIDE 14

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

Modeling of nanoparticles behavior in active systems through re- engineering of actual systems

LEGENDA:

SHORT TERM MEDIUM TERM LONG TERM

FINAL PRODUCT WASTE TREATMENT MODELLING MATERIALS TOOLS METROLOG Y COMPONENTS ASSEMBL Y

NON-TECH ACTIONS specific to the value chain

Methods for functionalization during synthesis to reduce production steps of nanofillers Development of technology able to produce in reproducible way complex nanomaterials Monitoring

  • f material

behavior in use Modeling for interface and functionalizatio n particles surface Design of multifunctional materials tailored for different needs SAFETY Adopt safety by design into material selection TRL 7-8 TRL 5-6 TRL 1-4 SAFETY Understand hazardous nature of the material appropriate to the specific route of application, and potential translocation of the released material in the human body SAFETY Characterise and control mechanical release of nanoparticles to the surface in biological systems. Understand hazardous nature of the material appropriate to the specific application, and potential translocation of the released material in the human body Improvements in the drug loading efficiency of lipid based nanoparticles, and synthetic inorganic nanomatrices and nanocapsules 2D – Integration of technologies with increased throughput and definition (S2S, HE, NIL, Laser, Litho…) 3D – Integration of structured films (plastic) into 3D parts and in-line process development

NMP 6 – 2015: Novel nanomatrices and nanocapsules

Examples of Actions in Medicine

Improvements in the drug loading efficiency of lipid based nanoparticles, and synthetic inorganic nanomatrices and nanocapsules

SHOT TERM

slide-15
SLIDE 15

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

Modeling of nanoparticles behavior in active systems through re- engineering of actual systems

LEGENDA:

SHORT TERM MEDIUM TERM LONG TERM

FINAL PRODUCT WASTE TREATMENT MODELLING MATERIALS TOOLS METROLOG Y COMPONENTS ASSEMBL Y

NON-TECH ACTIONS specific to the value chain

Methods for functionalization during synthesis to reduce production steps of nanofillers Development of technology able to produce in reproducible way complex nanomaterials Monitoring

  • f material

behavior in use Modeling for interface and functionalizatio n particles surface Design of multifunctional materials tailored for different needs SAFETY Adopt safety by design into material selection TRL 7-8 TRL 5-6 TRL 1-4 SAFETY Understand hazardous nature of the material appropriate to the specific route of application, and potential translocation of the released material in the human body SAFETY Characterise and control mechanical release of nanoparticles to the surface in biological systems. Understand hazardous nature of the material appropriate to the specific application, and potential translocation of the released material in the human body Improvements in the drug loading efficiency of lipid based nanoparticles, and synthetic inorganic nanomatrices and nanocapsules 2D – Integration of technologies with increased throughput and definition (S2S, HE, NIL, Laser, Litho…) 3D – Integration of structured films (plastic) into 3D parts and in-line process development

Examples of Actions in Medicine

2D – Integration of technologies with increased throughput and definition (S2S, HE, NIL, Laser, Litho…)

MEDIUM TERM

slide-16
SLIDE 16

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

Modeling of nanoparticles behavior in active systems through re- engineering of actual systems

LEGENDA:

SHORT TERM MEDIUM TERM LONG TERM

FINAL PRODUCT WASTE TREATMENT MODELLING MATERIALS TOOLS METROLOG Y COMPONENTS ASSEMBL Y

NON-TECH ACTIONS specific to the value chain

Methods for functionalization during synthesis to reduce production steps of nanofillers Development of technology able to produce in reproducible way complex nanomaterials Monitoring

  • f material

behavior in use Modeling for interface and functionalizatio n particles surface Design of multifunctional materials tailored for different needs SAFETY Adopt safety by design into material selection TRL 7-8 TRL 5-6 TRL 1-4 SAFETY Understand hazardous nature of the material appropriate to the specific route of application, and potential translocation of the released material in the human body SAFETY Characterise and control mechanical release of nanoparticles to the surface in biological systems. Understand hazardous nature of the material appropriate to the specific application, and potential translocation of the released material in the human body Improvements in the drug loading efficiency of lipid based nanoparticles, and synthetic inorganic nanomatrices and nanocapsules 2D – Integration of technologies with increased throughput and definition (S2S, HE, NIL, Laser, Litho…) 3D – Integration of structured films (plastic) into 3D parts and in-line process development

Examples of Actions in Medicine

Development of technology able to produce in reproducible way complex nanomaterials

Development of technology able to produce in reproducible way complex nanomaterials

LONG TERM

slide-17
SLIDE 17

Treviso 20-21 Nov. 2015

EXAMPLE

slide-18
SLIDE 18

Treviso 20-21 Nov. 2015

Encapsulated Magnetic Nanoparticles for Self Regulating Hyperthermia in Theranostic Oncology

Value Chain Example

Gherlinzoni Gottardi Matteazzi Patent

VALUE CHAIN PRODUCT CHAIN SOCIETAL CHAIN

Knowledge Design Growth Market Product Sustainability

slide-19
SLIDE 19

Treviso 20-21 Nov. 2015

Magnetic Field for Therapy Magnetic Field for Diagnosis

Theranostics = Therapy + Diagnosis

The functional nanoparticles are suitable for allowing:

  • «Real time» imaging
  • Evaluation of therapy evolution
  • Higher and safer control

Locally perform magnetic hyperthermia Contrast agents for MRI diagnosis

THERANOSTIC ¡APPROACH ¡

slide-20
SLIDE 20

Treviso 20-21 Nov. 2015 CONCLUSIONS ¡

Encapsulated Magnetic Nanoparticles for Self Regulating Hyperthermia in Theranostic Oncology

Intrinsically safe, by magnetic nanoparticles with self regulating heating Selective effectiveness, by shell functionalization for targeted delivery Powerful technique in Oncology, by theranostic approach

slide-21
SLIDE 21

Treviso 20-21 Nov. 2015

CONCEPTS MNPs DEVELOPMENT ENCAPSULATION

THERANOSTIC FUNCTIONALITIES

Magnetization 50 150 nm 100 Temperature, °C 40 50 30 60 Application Time Temperature, °C TC 40 50 30 60 TC HYPERTHERMIA 42 44 46 °C FILTRATION/SEPARATION TOXICOLOGICAL PROFILE Solvent System Non-Solvent System Inert Gas MNPS ENCAPSULATION DESIGN OF TARGET DELIVERING Biocompatibility Material Curie Temperature, °C Low High 100 150 50 200 Targeted Material Desing MNPs DESIGN HEBM Thermal Treatment HEBM MNPs PRODUCTION SELF REGULATING HEATING TARGETED HYPERTHERMIA TC MAGNETIC NANO PARTICLES PROOF OF THERANOSTIC CONCEPT

Pilot TRL Medium TRL LOW TRL

Development Status in the Value Chain

slide-22
SLIDE 22

Treviso 20-21 Nov. 2015

FIND ¡THE ¡ON ¡LINE ¡ROADMAP ¡DOCUMENTS: ¡

  • ­‑“Implementa+on ¡Roadmap ¡on ¡value ¡chains ¡

and ¡related ¡pilot ¡lines” ¡

  • ­‑“Appendix ¡to ¡the ¡Implementa+on ¡Roadmap ¡
  • n ¡value ¡chains ¡and ¡related ¡pilot ¡lines” ¡at: ¡ ¡

http://nanofutures.eu/documents

Please, ¡join ¡our ¡Open ¡Consulta+on ¡at: ¡

http://value4nano.eu

THANK ¡YOU ¡FOR ¡YOUR ¡ATTENTION ¡

GIVE A LOOK TO OUR VIDEO NANOfuture channel

slide-23
SLIDE 23

Treviso 20-21 Nov. 2015 Treviso 20-21 Nov. 2015

NANOfutures EITP

The EU scenario in nanotechnology and new perspective in cancer therapy